FDA accepts application for Merck’s Keytruda plus chemotherapy as first-line treatment for metastatic gastric

Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression

AIIA hosts walkthrough for Working Group of C20 on Integrated Holistic Health

MoU signed between AIIA and University of Amrita Vishwa Vidhyapeetham for collaboration in the field of Research and Academics in Ayurveda

Thermo Fisher Scientific expands its capabilities in France

Bourgoin early development hub broadens offerings for oral solid dose formulations

Emcure Pharmaceuticals bags Merit Award at HIV Congress 2023

The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.

Cognizant, Microsoft collaborate to bring cloud-based solutions to the healthcare market

Microsoft Cloud for Healthcare and Cognizant’s TriZetto healthcare products aim to enhance transparency for consumers and increase interoperability for providers and payers

Tillotts Pharma announces the launch of Octasa 1600 mg Tablets in Canada

The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.

mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma

Bridgewest Group launches new sterile injectable CDMO NovaCina

Lonza and ABL Bio collaborate on development and manufacture of new bispecific antibody product

Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution

SK Capital completes acquisition of Apotex